ScoreWhy is Suzhou Zelgen Biopharmaceuticals Co., Ltd. ?
1
With a growth in Net Sales of 44.22%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 921.42 MM
- ROCE(HY) Highest at 37.96%
- DEBTORS TURNOVER RATIO(HY) Highest at 8.06 times
2
With ROE of 28.92%, it has a fair valuation with a 16.50 Price to Book Value
- Over the past year, while the stock has generated a return of 13.15%, its profits have risen by 463.1% ; the PEG ratio of the company is 0.1
3
Consistent Returns over the last 3 years
- Along with generating 13.15% returns in the last 1 year, the stock has outperformed China Shanghai Composite in each of the last 3 annual periods
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Suzhou Zelgen Biopharmaceuticals Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Suzhou Zelgen Biopharmaceuticals Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
13.15%
1.88
62.71%
China Shanghai Composite
3.23%
0.23
14.72%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
124.93%
EBIT Growth (5y)
25.04%
EBIT to Interest (avg)
-20.63
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.92
Sales to Capital Employed (avg)
0.32
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
99.36%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
57
Industry P/E
Price to Book Value
16.50
EV to EBIT
59.79
EV to EBITDA
54.73
EV to Capital Employed
455.13
EV to Sales
17.19
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
761.20%
ROE (Latest)
28.92%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend38What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 921.42 MM
ROCE(HY)
Highest at 37.96%
DEBTORS TURNOVER RATIO(HY)
Highest at 8.06 times
NET SALES(Q)
At CNY 299.99 MM has Grown at 44.22%
PRE-TAX PROFIT(Q)
At CNY 5.88 MM has Grown at 112.48%
NET PROFIT(Q)
At CNY 6.4 MM has Grown at 114.37%
RAW MATERIAL COST(Y)
Fallen by -0.13% (YoY
CASH AND EQV(HY)
Highest at CNY 5,153.35 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -94.04 %
INVENTORY TURNOVER RATIO(HY)
Highest at 0.78 times
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Net Sales
At CNY 299.99 MM has Grown at 44.22%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (CNY MM)
Pre-Tax Profit
At CNY 5.88 MM has Grown at 112.48%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 6.4 MM has Grown at 114.37%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Debtors Turnover Ratio
Highest at 8.06 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Cash Flow
Highest at CNY 921.42 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Cash and Eqv
Highest at CNY 5,153.35 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -94.04 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 0.78 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -0.13% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Non Operating Income
Highest at CNY 4.44 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
Footer loading
